Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INCB086550 |
Synonyms | |
Therapy Description |
INCB086550 is a small molecule PD-L1 (CD274) inhibitor that prevents PD-L1/PD-1 interaction, potentially leading to enhanced anti-tumor immune response (PMID: 35254416). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB086550 | INCB 086550|INCB-086550 | Immune Checkpoint Inhibitor 147 PD-L1 Inhibitor 13 | INCB086550 is a small molecule PD-L1 (CD274) inhibitor that prevents PD-L1/PD-1 interaction, potentially leading to enhanced anti-tumor immune response (PMID: 35254416). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03762447 | Phase I | INCB086550 | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 0 |